You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Claims for Patent: 5,334,504

✉ Email this page to a colleague

Summary for Patent: 5,334,504

Title:	In vitro assay for detecting cell-mediated immune responses
Abstract:	An in vitro method of detecting a cell-mediated immune response to a specific antigen, comprising incubating a whole blood sample with the specific antigen and detecting the presence of gamma interferon released by sensitized lymphocytes in the whole blood sample as an indication of a cell-mediated immune response to the specific antigen.
Inventor(s):	Wood; Paul R. (Lower Templestowe, AU), Corner; Leigh A. (Romsey, AU)
Assignee:	Commonwealth Scientific & Industrial Research Organisation (Campbell, AU)
Application Number:	08/124,439
Patent Claims:	1. An in vitro method of detecting a cell-mediated immune response to a specific antigen in a human or animal, which comprises the steps of: (i) incubating a whole blood sample from the human or animal with the specific antigen; and (ii) detecting the presence of gamma interferon (.gamma.IFN) released by sensitized lymphocytes in said whole blood sample to indicate a cell-mediated immune response to said specific antigen. 2. A method according to claim 1, wherein said step of detecting the presence of gamma interferon is an immunoassay for gamma interferon. 3. A method according to claim 2, wherein said immunoassay is an enzyme-linked immunosorbent assay (ELISA) or a radio-immunoassay (RIA) for gamma interferon. 4. A method according to claim 1, for the detection of M.bovis infections in cattle, wherein said specific antigen is the M.bovis antigen, tuberculin purified protein derivative (PPD). 5. A method according to claim 1 wherein said specific antigen is an antigen of Mycobacterium bovis, Mycobacterium paratuberculosis or Mycobacterium tuberculosis. 6. A method according to claim 2 wherein said specific antigen is an antigen of Mycobacterium bovis, Mycobacterium paratuberculosis or Mycobacterium tuberculosis. 7. A method according to claim 3 wherein said specific antigen is an antigen of Mycobacterium bovis, Mycobacterium paratuberculosis or Mycobacterium tuberculosis.

Details for Patent 5,334,504

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Par Pharmaceutical Companies, Inc.	APLISOL	tuberculin, purified protein derivative	Injection	103782	April 20, 1998	⤷ Start Trial	2013-09-22
Sanofi Pasteur Limited	TUBERSOL	tuberculin, purified protein derivative	Injection	103941	February 24, 2000	⤷ Start Trial	2013-09-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.